Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1BT2M
|
|||
| Drug Name |
NJA-730
|
|||
| Drug Type |
Antisense oligonucleotide
|
|||
| Indication | Graft-versus-host disease [ICD-11: 4B24; ICD-9: 279.5] | Phase 1 | [1] | |
| Company |
NapaJen Pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | CD40 messenger RNA (CD40 mRNA) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NF-kappa B signaling pathway | ||||
| Cell adhesion molecules (CAMs) | ||||
| Toll-like receptor signaling pathway | ||||
| Intestinal immune network for IgA production | ||||
| Malaria | ||||
| Toxoplasmosis | ||||
| HTLV-I infection | ||||
| Epstein-Barr virus infection | ||||
| Transcriptional misregulation in cancer | ||||
| Asthma | ||||
| Autoimmune thyroid disease | ||||
| Systemic lupus erythematosus | ||||
| Allograft rejection | ||||
| Primary immunodeficiency | ||||
| Viral myocarditis | ||||
| Pathway Interaction Database | CD40/CD40L signaling | |||
| WikiPathways | Toll-like receptor signaling pathway | |||
| Inflammatory Response Pathway | ||||
| NLR Proteins | ||||
| Human Complement System | ||||
| Allograft Rejection | ||||
| Regulation of toll-like receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of NapaJen Pharma. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.